Autolus Ltd. added Cynthia Butitta to its board.
Butitta previously worked as the COO of Kite Pharma Inc. until its $11.9 billion acquisition by Gilead Sciences Inc. She also served as Kite Pharma's CFO from January 2014 to May 2016.
London-based Autolus is a privately held biotechnology company that develops T cell immunotherapies to treat cancer. It recently filed for a potential U.S. IPO
